Navigation Links
Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization
Date:12/13/2012

nd uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2011, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... and FARMINGTON, Conn. , ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of Series E warrants to purchase 21,917,808 ... warrants to purchase 2,191,781 shares of its common ...
(Date:7/6/2015)... , July 6, 2015  Impax Laboratories, Inc. ... Hsu , Ph.D. has resigned from the Company,s Board ... Dr. Hsu was a co-founder of Impax in 1995 ... Officer from October 2006 until April 2014. ... Wilkinson , Impax,s President and Chief Executive Officer stated, ...
(Date:7/6/2015)... DIEGO , July 6, 2015  OncoSec Medical ... DNA-based intratumoral cancer immunotherapies, today announced the appointment of ... position of Vice President of Market Development, effective July ... responsible for evaluating, designing, and executing on the company,s ... "I,m very excited to welcome Joann to ...
Breaking Medicine Technology:Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3
... production, increasing blood ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. ... Hypertension Research reveals Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark ... oxide,(NO) production which leads to an increase in blood flow and ...
... Developed Through Joint Venture Between Bristol-Myers Squibb, ... Its Kind in HIV Treatment -, PRINCETON, ... Bristol-Myers Squibb Company (NYSE: BMY ) and ... that Health Canada has approved ATRIPLA(R),(efavirenz 600 mg/emtricitabine ...
Cached Medicine Technology:New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 2New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9
(Date:7/5/2015)... ... ... Women's Excellence in Wellness, powered by Movestrong announces parent/child fitness classes ... families that want their children to stay active as well as spend time with ... place TUESDAYS at 4:30pm. Questions? Call 248-601-6683. Women’s Excellence in Wellness, powered by ...
(Date:7/4/2015)... ... 04, 2015 , ... Earlier in 2015, on Feb. 26, ... member survey , detailing the most common plastic surgery and minimally invasive cosmetic ... data down into charts detailing demographic trends and regional preferences. With a focus ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... on July 2nd creating a buzz of media attention. In an effort to ... by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people are feeling overwhelmed by ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, ... retained to lead a national president recruitment for Regional Care, Inc. ... industry, B. E. Smith has recently placed more than 1,000 healthcare executives into ...
(Date:7/3/2015)... ... July 03, 2015 , ... Jennifer Renee Hanes, DO is ... Room , the largest network of independent freestanding emergency rooms in the United States. ... of our Sienna Plantation facility,” said Executive Medical Director of First Choice Emergency Room, ...
Breaking Medicine News(10 mins):Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3
... from Japan specifically for event -, MCLEAN, ... robotic baby,harp seal more effective than real, live ... with dementia and other aging-related,illnesses?, Come find ... when Vinson Hall,Retirement Community (VHRC) in McLean, Va., ...
... Study Published in Journal of Occupational and Environmental Medicine, Investigates ... ... Resource Utilization, PHILADELPHIA, May 12 High ... total,healthcare costs, according to a new study published this month ...
... (SPECT), researchers in The Netherlands were able to ... with generalized social anxiety disorder (also known as ... cause for the dysfunction. , The study, which ... Journal of Nuclear Medicine, compared densities of elements ...
... diet to look more attractive. Fish diet to avoid ... and getting eaten as a result. , That is the ... researchers from the ARC Centre of Excellence for Coral Reef ... Current Biology. , The same team who recently revealed fish ...
... May 12 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer ... operating room, today announced financial results for the first,quarter ended ... dollar amounts are expressed in US dollars., Q1 ... 14 new SPY systems installed, 22% increase ...
... the following preliminary,unaudited net sales results for the month of April 2008 by segment:, , ... (Preliminary and Unaudited) ... MONTH OF APRIL ... ...
Cached Medicine News:Health News:Paro, the World's Only Robotic Baby Harp Seal - Designed Specifically for Therapy - to be Focus of Industry Event at Vinson Hall Retirement Community in McLean, Va., June 2 2Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 2Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 3Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 4Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 5Health News:Are anxiety disorders all in the mind? 2Health News:Fish diet to avoid fights 2Health News:Novadaq Reports Financial Results for the First Quarter of 2008 2Health News:Novadaq Reports Financial Results for the First Quarter of 2008 3Health News:Novadaq Reports Financial Results for the First Quarter of 2008 4Health News:Novadaq Reports Financial Results for the First Quarter of 2008 5Health News:Novadaq Reports Financial Results for the First Quarter of 2008 6Health News:Novadaq Reports Financial Results for the First Quarter of 2008 7Health News:Novadaq Reports Financial Results for the First Quarter of 2008 8Health News:Novadaq Reports Financial Results for the First Quarter of 2008 9Health News:Novadaq Reports Financial Results for the First Quarter of 2008 10Health News:Novadaq Reports Financial Results for the First Quarter of 2008 11Health News:NBTY Announces Preliminary Unaudited Net Sales Results for April 2008 2
... excellent classical blood film stain used ... marrow. Erythrocytes stain pink to buff ... pale pink. Leukocyte nuclear chromatin stains ... "ground glass" blue and lymphocyte cytoplasm ...
RABIT (Rapid Automated Bacterial Impedance Technique) has been developed by Don Whitley Scientific over several years with the aid of leading product and computer design consultants....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
Albumin reagent is used for the quantitative determination of albumin concentration in human serum....
Medicine Products: